查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571951

液态切片的全球市场

Breast Cancer Liquid Biopsy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 89 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计2030年全球液态切片市场将达到11亿美元

2023年全球液态切片市场估计为2.779亿美元，预计到2030年将达到11亿美元，2023-2030年分析期间复合年增长率为21.4%。试剂组是本报告分析的细分市场之一，预计复合年增长率为 22.0%，到分析期结束时将达到 8.193 亿美元。分析期间内，设备领域的复合年增长率预计为 21.0%。

美国市场预计7,700万美元，中国预期复合年增长率20.4%

预计 2023 年美国液态切片市场规模将达到 7,700 万美元。中国作为全球第二大经济体，预计2030年市场规模将达到1.614亿美元，2023-2030年分析期间复合年增长率为20.4%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 19.0% 和 18.4%。在欧洲，德国的复合年增长率预计约为 15.8%。

全球液态切片市场 - 主要趋势和驱动因素总结

液态切片将如何彻底改变乳癌的诊断和治疗？

液态切片提供了一种微创方法，透过分析循环性肿瘤细胞(CTC)、循环肿瘤DNA (ctDNA) 以及血液和其他体液中存在的其他生物标记来检测和监测癌症。正在彻底改变诊断方法。传统上，乳癌的诊断在很大程度上依赖组织切片检查，即透过手术切除肿瘤样本并进行分析。液态切片提供了一种侵入性较小的替代方案，可以频繁监测和早期检测基因突变、抗治疗性和肿瘤进展，而无需手术。这对于因健康状况或肿瘤位置而无法重复侵入性手术的患者尤其有益。

液态切片技术的关键进步之一是它能够即时了解癌症的分子特征并实现个人化治疗策略。透过分析ctDNA和CTC，肿瘤学家可以识别驱动癌症进展的特定基因突变，例如HER2和BRCA突变，这可以指南标靶治疗的选择。此外，液态切片可以持续监测治疗效果，使医生能够及早发现抗药性并相应调整治疗计划。这种精准医疗方法正在为患者提供更个人化、有效且适应性强的治疗选择，从而改变乳癌的治疗方法。

液态切片在乳癌的早期检测和监测中发挥什么作用？

液态切片在乳癌的早期检测和监测中发挥着重要作用，它使临床医生能够在透过影像或身体检查检测到癌症突变和肿瘤动态变化之前识别它们。早期乳癌通常无症状，传统的诊断方法（例如乳房X光检查和组织切片检查）可能会漏掉小或早期的病灶。然而，液态切片可以检测到肿瘤排放到血流中的微量 ctDNA，从而提供了一种早期检测癌症的非侵入性方法。早期检测可以增加治疗成功的可能性并降低转移风险，这对于改善患者预后至关重要。

除了早期检测之外，液态切片还可用于在乳癌患者的整个病人历程过程中进行持续监测。透过追踪 ctDNA 或 CTC 水平的变化，临床医生可以评估患者对治疗的反应情况，检测微量残存疾病(MRD)，并透过传统影像方式检测明显的肿瘤生长，您可以在復发迹象发生之前识别。这种即时监测癌症进展的能力可以实现更动态和个人化的治疗计划，提高整体存活率并减少对更具侵入性检测的需求。随着液态切片技术的不断发展，预计它将成为乳癌早期检测和长期患者监测的标准工具。

液态切片如何推进乳癌的个人化医疗？

液态切片能够更深入了解每位患者肿瘤的遗传和分子状况，处于推动乳癌个人化医疗的最前线。透过ctDNA分析，液态切片可以识别特定的基因突变，例如PIK3CA、ESR1和BRCA1/2。这些资讯使肿瘤学家能够根据每位患者独特的癌症特征量身定制治疗方案，并根据可操作突变的存在选择最有效的治疗方法。例如，HER2 阳性乳癌患者可能受益于曲妥珠单抗等标靶治疗，而 BRCA 突变患者可能对 PARP 抑制剂有更好的反应。

液态切片还可以帮助识别抗治疗性的出现，这是乳癌治疗的通用挑战。随着时间的推移，癌细胞可以获得新的突变，帮助它们逃避化疗和标靶治疗的作用。液态切片使临床医生能够及早发现这些抗药性突变，从而有可能使他们能够在癌症进一步进展之前调整治疗策略或转向替代疗法。透过提供对肿瘤进展的即时分子洞察，液态切片正在为个人化医疗方法提供动力，以优化乳癌患者的治疗效果并最大程度地减少不必要的副作用。

推动液态切片市场成长的因素有哪些？

液态切片市场的成长是由几个关键因素推动的，例如对非侵入性诊断方法的需求不断增加、精准医学的进步以及全球乳癌发病率的上升。液态切片提供了一种比组织切片检查更安全、侵入性更小的替代方法，因此患者选择这种方法，特别是对于需要频繁监测或不适合传统切片检查和医疗保健提供者的患者。在治疗期间进行重复液态切片的能力还可以持续监测疾病进展，有助于改善患者的治疗结果。

液态切片平台的技术进步，例如次世代定序(NGS) 和数位 PCR，正在提高这些测试的灵敏度和准确性，进一步推动市场采用。对个人化医疗和标靶治疗的日益关注也是推动市场成长的关键因素，因为液态切片提供了为个别患者量身定制治疗所需的分子见解。此外，全球乳癌发生率的增加增加了对早期检测和监测工具的需求，从而促进了液态切片市场的扩大。随着医疗保健系统越来越重视精准肿瘤学和非侵入性诊断，液态切片市场预计将在未来几年持续成长。

受访企业范例（34家知名企业）

  • Biodesix, Inc.
  • Bio-Rad Laboratories
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina
  • Isogen Life Science BV
  • Menarini Silicon Biosystems
  • Myriad Genetics

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP21384

Global Breast Cancer Liquid Biopsy Market to Reach US$1.1 Billion by 2030

The global market for Breast Cancer Liquid Biopsy estimated at US$277.9 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 21.4% over the analysis period 2023-2030. Reagent Kits, one of the segments analyzed in the report, is expected to record a 22.0% CAGR and reach US$819.3 Million by the end of the analysis period. Growth in the Instruments segment is estimated at 21.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$77.0 Million While China is Forecast to Grow at 20.4% CAGR

The Breast Cancer Liquid Biopsy market in the U.S. is estimated at US$77.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$161.4 Million by the year 2030 trailing a CAGR of 20.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.0% and 18.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.8% CAGR.

Global Breast Cancer Liquid Biopsy Market – Key Trends & Drivers Summarized

How Are Liquid Biopsies Transforming Breast Cancer Diagnosis and Treatment?

Liquid biopsies are revolutionizing breast cancer diagnosis and treatment by providing a minimally invasive method for detecting and monitoring cancer through the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other biomarkers present in blood or other bodily fluids. Traditionally, breast cancer diagnosis relied heavily on tissue biopsies, which involve surgically removing a sample of the tumor for analysis. Liquid biopsies offer a less invasive alternative, allowing for frequent monitoring and early detection of genetic mutations, treatment resistance, and tumor progression without the need for surgery. This is particularly beneficial for patients who cannot undergo repeated invasive procedures due to health conditions or the location of the tumor.

One of the key advancements in liquid biopsy technology is its ability to provide real-time insights into the molecular profile of the cancer, enabling personalized treatment strategies. By analyzing ctDNA and CTCs, oncologists can identify specific genetic mutations driving the cancer, such as HER2 or BRCA mutations, which can guide the selection of targeted therapies. Moreover, liquid biopsies allow for the continuous monitoring of treatment effectiveness, helping doctors detect drug resistance early and adjust treatment plans accordingly. This precision medicine approach is transforming breast cancer care by offering more personalized, effective, and adaptive treatment options for patients.

What Role Do Liquid Biopsies Play in Early Detection and Monitoring of Breast Cancer?

Liquid biopsies play a crucial role in the early detection and monitoring of breast cancer by allowing clinicians to identify cancerous mutations and changes in tumor dynamics before they become detectable through imaging or physical examination. Early-stage breast cancer is often asymptomatic, and traditional diagnostic methods such as mammograms or tissue biopsies may miss small or early lesions. Liquid biopsies, however, can detect minute amounts of ctDNA shed by tumors into the bloodstream, providing a non-invasive method to identify cancer at an earlier stage. Early detection is critical for improving patient outcomes, as it increases the chances of successful treatment and reduces the risk of metastasis.

In addition to early detection, liquid biopsies are valuable for ongoing monitoring of breast cancer patients throughout their treatment journey. By tracking changes in ctDNA or CTC levels, clinicians can assess how well a patient is responding to therapy, detect minimal residual disease (MRD), and identify signs of relapse before traditional imaging methods reveal tumor growth. This ability to monitor cancer progression in real time allows for more dynamic and personalized treatment plans, improving overall survival rates and reducing the need for more invasive tests. As liquid biopsy technology continues to evolve, it is expected to become a standard tool in both early breast cancer detection and long-term patient monitoring.

How Are Liquid Biopsies Advancing Personalized Medicine in Breast Cancer?

Liquid biopsies are at the forefront of advancing personalized medicine in breast cancer by enabling a deeper understanding of the genetic and molecular landscape of each patient’s tumor. Through the analysis of ctDNA, liquid biopsies can identify specific genetic mutations, such as PIK3CA, ESR1, or BRCA1/2, which may influence how a patient responds to certain therapies. This information allows oncologists to tailor treatments to the individual patient’s unique cancer profile, selecting therapies that are most likely to be effective based on the presence of actionable mutations. For example, patients with HER2-positive breast cancer may benefit from targeted therapies like trastuzumab, while those with BRCA mutations may respond better to PARP inhibitors.

Liquid biopsies also help in identifying the emergence of treatment resistance, a common challenge in breast cancer management. Over time, cancer cells can acquire new mutations that allow them to evade the effects of chemotherapy or targeted therapies. Liquid biopsies enable clinicians to detect these resistance mutations early, allowing them to adjust treatment strategies and potentially switch to alternative therapies before the cancer progresses further. By providing real-time, molecular-level insights into the tumor’s evolution, liquid biopsies are empowering personalized medicine approaches that optimize treatment efficacy and minimize unnecessary side effects for breast cancer patients.

What Factors Are Driving the Growth of the Breast Cancer Liquid Biopsy Market?

The growth of the breast cancer liquid biopsy market is driven by several key factors, including the increasing demand for non-invasive diagnostic methods, advancements in precision medicine, and the rising incidence of breast cancer globally. As liquid biopsies offer a safer, less invasive alternative to tissue biopsies, more patients and healthcare providers are opting for this approach, particularly for patients who require frequent monitoring or those who are not candidates for traditional biopsies. The ability to perform repeated liquid biopsies over the course of treatment also allows for continuous monitoring of disease progression, helping to improve patient outcomes.

Technological advancements in liquid biopsy platforms, such as next-generation sequencing (NGS) and digital PCR, are enhancing the sensitivity and accuracy of these tests, further driving market adoption. The growing focus on personalized medicine and targeted therapies is another major factor fueling market growth, as liquid biopsies provide the molecular insights needed to tailor treatments to individual patients. Additionally, the increasing prevalence of breast cancer worldwide is creating a higher demand for early detection and monitoring tools, contributing to the expansion of the liquid biopsy market. As healthcare systems increasingly prioritize precision oncology and non-invasive diagnostics, the breast cancer liquid biopsy market is expected to experience sustained growth in the coming years.

Select Competitors (Total 34 Featured) -

  • Biodesix, Inc.
  • Bio-Rad Laboratories
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina
  • Isogen Life Science B.V.
  • Menarini Silicon Biosystems
  • Myriad Genetics

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Breast Cancer Liquid Biopsy - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Breast Cancer Globally Drives Growth in the Breast Cancer Liquid Biopsy Market
    • Increasing Demand for Non-Invasive Diagnostics Expands the Addressable Market for Liquid Biopsies in Breast Cancer
    • Technological Advancements in Circulating Tumor DNA (ctDNA) and Cell-Free DNA (cfDNA) Testing Propel Innovation in Breast Cancer Liquid Biopsy
    • Growing Focus on Early Detection and Monitoring of Breast Cancer Strengthens the Business Case for Liquid Biopsy Solutions
    • Rising Adoption of Liquid Biopsies in Precision Medicine and Targeted Therapy Selection Fuels Market Growth
    • Increasing Use of Liquid Biopsies in Monitoring Treatment Response and Disease Recurrence Expands Applications in Breast Cancer Care
    • Technological Innovations in Next-Generation Sequencing (NGS) Propel Growth in High-Sensitivity Liquid Biopsy Platforms
    • Growing Focus on Minimally Invasive Cancer Diagnostics Expands the Market for Breast Cancer Liquid Biopsy
    • Rising Investment in Biomarker Discovery and Validation Strengthens Market Growth for Breast Cancer Liquid Biopsies
    • Growing Use of Liquid Biopsy for Companion Diagnostics in Breast Cancer Therapies Expands Market Reach
    • Technological Advancements in Exosome-Based and Protein Biomarker Detection Propel Growth in Breast Cancer Liquid Biopsies
    • Rising Focus on Liquid Biopsy for Real-Time Cancer Monitoring and Personalized Treatment Drives Adoption in Oncology
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Breast Cancer Liquid Biopsy Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Breast Cancer Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Prognostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Risk Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Risk Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Risk Assessment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Reagent Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Reagent Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Reagent Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Circulating Tumor Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Extracellular Vesicles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Circulating Tumor DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • JAPAN
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • CHINA
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • EUROPE
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Breast Cancer Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • FRANCE
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • GERMANY
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030

IV. COMPETITION